Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vanderbilt's Neuroscience Unit Operates Like A Biotech

This article was originally published in Start Up

Executive Summary

A small drug-discovery shop within Vanderbilt University Medical Center shows how a focused approach can lead to top-notch results in the so-called translational research space. The Vanderbilt Center for Neuroscience Drug Discovery, continues to garner NIH grants as well as milestone-based payments from the biopharma industry via serially inking drug discovery deals centered around one specialized area: addressing brain-linked disorders through the modulation of glutamate receptors.

You may also be interested in...



Academic Drug-Discovery Units Team Up To Share Knowledge, Facilitate Partnering

Founded in 2012, the Academic Drug Discovery Consortium intends to serve as a clearinghouse for both academia and industry on research underway at U.S. and international drug research programs. It won’t undertake tech transfer work itself, but the ADDC hopes to make it easier for academics and biopharma to work together.

AstraZeneca Teams With Vanderbilt In Neuroscience Pact

Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.

Deals Of The Week: United Therapeutics/Ascendis, Baxter/Onconova, Bionomics/Eclipse

The growing importance of emerging markets was a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel